JP2010514831A5 - - Google Patents

Download PDF

Info

Publication number
JP2010514831A5
JP2010514831A5 JP2009544450A JP2009544450A JP2010514831A5 JP 2010514831 A5 JP2010514831 A5 JP 2010514831A5 JP 2009544450 A JP2009544450 A JP 2009544450A JP 2009544450 A JP2009544450 A JP 2009544450A JP 2010514831 A5 JP2010514831 A5 JP 2010514831A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
table below
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009544450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514831A (ja
Filing date
Publication date
Priority claimed from GB0700125A external-priority patent/GB0700125D0/en
Priority claimed from GB0708746A external-priority patent/GB0708746D0/en
Priority claimed from GB0719763A external-priority patent/GB0719763D0/en
Application filed filed Critical
Priority claimed from PCT/GB2008/050013 external-priority patent/WO2008081207A1/en
Publication of JP2010514831A publication Critical patent/JP2010514831A/ja
Publication of JP2010514831A5 publication Critical patent/JP2010514831A5/ja
Pending legal-status Critical Current

Links

JP2009544450A 2007-01-04 2008-01-04 ピペリジンgpcrアゴニスト Pending JP2010514831A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0700125A GB0700125D0 (en) 2007-01-04 2007-01-04 GPCR agonists
GB0708746A GB0708746D0 (en) 2007-05-08 2007-05-08 GPCR agonists
GB0719763A GB0719763D0 (en) 2007-10-10 2007-10-10 GPCR agonists
PCT/GB2008/050013 WO2008081207A1 (en) 2007-01-04 2008-01-04 Piperidine gpcr agonists

Publications (2)

Publication Number Publication Date
JP2010514831A JP2010514831A (ja) 2010-05-06
JP2010514831A5 true JP2010514831A5 (enExample) 2011-02-24

Family

ID=39199058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009544450A Pending JP2010514831A (ja) 2007-01-04 2008-01-04 ピペリジンgpcrアゴニスト

Country Status (20)

Country Link
US (1) US20100105732A1 (enExample)
EP (2) EP2114935B1 (enExample)
JP (1) JP2010514831A (enExample)
AR (1) AR064735A1 (enExample)
AT (1) ATE517103T1 (enExample)
BR (1) BRPI0806500A2 (enExample)
CA (1) CA2674455A1 (enExample)
CL (1) CL2008000018A1 (enExample)
CY (1) CY1112474T1 (enExample)
DK (1) DK2114935T3 (enExample)
EA (1) EA015130B1 (enExample)
HR (1) HRP20110750T1 (enExample)
PE (1) PE20081659A1 (enExample)
PL (1) PL2114935T3 (enExample)
PT (1) PT2114935E (enExample)
RS (1) RS51943B (enExample)
SA (1) SA08280757B1 (enExample)
SI (1) SI2114935T1 (enExample)
TW (1) TW200835482A (enExample)
WO (1) WO2008081207A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070091038A (ko) * 2004-12-24 2007-09-06 프로시디온 리미티드 G-단백질 결합 수용체(gpr116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도
AU2006264649A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
KR101396696B1 (ko) 2007-10-10 2014-05-16 노파르티스 아게 스피로피롤리딘, 및 hcv 및 hiv 감염에 대한 그의 용도
GB0812641D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
ES2403120T3 (es) 2008-12-24 2013-05-14 Cadila Healthcare Limited Nuevos derivados de oxima
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104610393A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途
CN104610390A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
US5252586A (en) * 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4222565A1 (de) * 1992-07-09 1994-01-13 Hoechst Ag Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
DE4311967A1 (de) * 1993-04-10 1994-10-13 Hoechst Ag Smektische Flüssigkristallmischung
DE4311968A1 (de) * 1993-04-10 1994-10-20 Hoechst Ag Smektische Flüssigkristallmischung
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
FR2705346B1 (fr) * 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 5員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
CA2262569A1 (en) 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
CA2344591A1 (en) 1998-09-01 2000-03-09 Basf Aktiengesellschaft Methods for improving the function of heterologous g protein-coupled receptors
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
WO2002042274A1 (en) * 2000-11-21 2002-05-30 Mitsubishi Chemical Corporation Process for producing 2-(4-pyridyl)ethanethiol
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
CN101659639A (zh) 2001-09-21 2010-03-03 索尔瓦药物有限公司 具有cb1-拮抗活性的新的4,5-二氢-1h-吡唑衍生物
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
KR100950430B1 (ko) 2001-09-21 2010-04-02 솔베이 파마슈티칼스 비. 브이 효력있는 cb1-길항 작용을 가지는4,5-디하이드로-1h-피라졸 유도체
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2833842B1 (fr) 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
AU2003219934A1 (en) 2002-03-06 2003-09-22 Merck And Co., Inc. Method of treatment or prevention of obesity
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
AU2003215024B2 (en) 2002-03-26 2008-02-21 Merck Sharp & Dohme Corp. Spirocyclic amides as cannabinoid receptor modulators
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
AU2003226149A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
AU2003296895A1 (en) 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
HRP20050053A2 (en) 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
BR0314872A (pt) 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
GB0230087D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
TW200413328A (en) 2003-01-02 2004-08-01 Hoffmann La Roche Novel CB 1 receptor inverse agonists
ES2309383T3 (es) 2003-01-02 2008-12-16 Hoffmann La Roche Pirrolil tiazoles y su empleo como agonistas inversos de receptores cb1.
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
ATE472548T1 (de) 2003-02-13 2010-07-15 Sanofi Aventis Deutschland Substituierte hexahydro-pyrazino(1,2-a)pyrimidin- 4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU2004212043A1 (en) 2003-02-13 2004-08-26 Sanofi-Aventis Deutschland Gmbh Nitrogen-substituted hexahydropyrazino(1,2-a)pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
WO2004078261A1 (en) 2003-03-07 2004-09-16 The University Court Of The University Of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AR045496A1 (es) * 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
KR20070091038A (ko) 2004-12-24 2007-09-06 프로시디온 리미티드 G-단백질 결합 수용체(gpr116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
AU2006264649A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
JP2008545010A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Gタンパク質共役受容体アゴニスト
JP2008545008A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Gpcrアゴニスト
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
NZ571869A (en) * 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists
JP5330260B2 (ja) * 2006-12-06 2013-10-30 スミスクライン ビーチャム コーポレーション 二環式化合物ならびに抗糖尿病薬としての使用
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr

Similar Documents

Publication Publication Date Title
JP2010514829A5 (enExample)
JP2010514832A5 (enExample)
JP2011527332A5 (enExample)
JP2011527333A5 (enExample)
JP2011500658A5 (enExample)
JP2011527331A5 (enExample)
RU2470016C2 (ru) Производное бипиразола
JP2011500659A5 (enExample)
JP2011522897A5 (enExample)
JP2011527334A5 (enExample)
JP2011527335A5 (enExample)
JP2018518537A5 (enExample)
JP2008525416A5 (enExample)
JP2010514828A5 (enExample)
JP2006143751A5 (enExample)
JP2009533410A5 (enExample)
JP2008007519A5 (enExample)
RU2009135016A (ru) Твердые формы, содержащие (-)-о-десметилвенлафаксин, и их применения
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
JP2010077141A5 (enExample)
JP2007500720A5 (enExample)
JP2012512907A5 (enExample)
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
JP2008533007A5 (enExample)
JP2012520866A5 (enExample)